ISL
PFE icon

Ingalls & Snyder LLC’s Pfizer PFE Stock Holding History

Ingalls & Snyder LLC’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-58,400
Closed -$1.48M – 483
2025
Q1 		$1.48M Hold
58,400
– – 0.05% 182
2024
Q4 		$1.55M Hold
58,400
– – 0.06% 167
2024
Q3 		$1.69M Hold
58,400
– – 0.07% 169
2024
Q2 		$1.63M Sell
58,400
-700
-1% -$19.3K 0.07% 164
2024
Q1 		$1.64M Buy
59,100
+33,000
+126% +$916K 0.07% 164
2023
Q4 		$751K Buy
+26,100
New +$789K 0.03% 241

Other funds holding PFE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Ingalls & Snyder LLC's PFE Position: Q1 2026 in Review

Ingalls & Snyder LLC reduced its Pfizer (PFE) stake by 1.4% in Q1 2026, selling an estimated $263K and leaving 708,097 shares worth $19.9M. The position accounts for 0.7% of the portfolio, ranked #34.

Ingalls & Snyder LLC first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $34.2M in Q4 2021. 2,938 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Ingalls & Snyder LLC held 708,097 shares of Pfizer worth $19.9M as of Q1 2026.
  • Ingalls & Snyder LLC sold 9,885 Pfizer shares in Q1 2026, an estimated $263K.
  • Pfizer made up 0.7% of Ingalls & Snyder LLC's portfolio in Q1 2026, its #34 holding.
  • Ingalls & Snyder LLC first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Ingalls & Snyder LLC's Pfizer position peaked at $34.2M in Q4 2021.
  • 2,938 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2026, filed 13 May 2026.